Clinical and immunological outcome in cutaneous leishmaniasis patients treated with pentoxifylline
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2014 |
| Outros Autores: | , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
| Texto Completo: | https://www.arca.fiocruz.br/handle/icict/24887 |
Resumo: | CARVALHO FILHO, Edgar Marcelino de. “Documento produzido em parceria ou por autor vinculado à Fiocruz, mas não consta à informação no documento”. |
| id |
CRUZ_4a3ea66493b92364566e4455cd6f6b52 |
|---|---|
| oai_identifier_str |
oai:www.arca.fiocruz.br:icict/24887 |
| network_acronym_str |
CRUZ |
| network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| repository_id_str |
2135 |
| spelling |
Brito, Maria das Graças de OliveiraDourado, Mayra Elizabeth FerreiraPolari, LudmilaCelestino, DanielaCarvalho, Lucas Pedreira deQueiroz, AdrianoCarvalho Filho, Edgar MarcelinoMachado, Paulo Roberto LimaPassos, Sara Timoteo2018-02-20T15:58:56Z2018-02-20T15:58:56Z2014BRITO, M. G. O. et al. Clinical and immunological outcome in cutaneous leishmaniasis patients treated with pentoxifylline. American Journal of Tropical Medicine and Hygiene, v. 90, n. 4, p. 617–620, 2014.0002-9637https://www.arca.fiocruz.br/handle/icict/2488710.4269/ajtmh.12-0729CARVALHO FILHO, Edgar Marcelino de. “Documento produzido em parceria ou por autor vinculado à Fiocruz, mas não consta à informação no documento”.INCT-DT 573839/2008-5 and ICIDR grant AI088650.Universidade Federal da Bahia. Complexo Hospital Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil / National Institute of Science and Technology–Tropical Disease. Salvador, BA, Brasil / Universidade Federal da Bahia. Instituto de Ciências da Saúde. Salvador, BA, BrasilUniversidade Federal da Bahia. Complexo Hospital Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil / National Institute of Science and Technology–Tropical Disease. Salvador, BA, Brasil / Universidade Federal da Bahia. Instituto de Ciências da Saúde. Salvador, BA, BrasilUniversidade Federal da Bahia. Complexo Hospital Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil / National Institute of Science and Technology–Tropical Disease. Salvador, BA, Brasil / Universidade Federal da Bahia. Instituto de Ciências da Saúde. Salvador, BA, BrasilUniversidade Federal da Bahia. Complexo Hospital Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil / National Institute of Science and Technology–Tropical Disease. Salvador, BA, Brasil / Universidade Federal da Bahia. Instituto de Ciências da Saúde. Salvador, BA, BrasilUniversidade Federal da Bahia. Complexo Hospital Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil / National Institute of Science and Technology–Tropical Disease. Salvador, BA, Brasil / Universidade Federal da Bahia. Instituto de Ciências da Saúde. Salvador, BA, BrasilUniversidade Federal da Bahia. Complexo Hospital Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil / National Institute of Science and Technology–Tropical Disease. Salvador, BA, Brasil / Universidade Federal da Bahia. Instituto de Ciências da Saúde. Salvador, BA, BrasilUniversidade Federal da Bahia. Complexo Hospital Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil / National Institute of Science and Technology–Tropical Disease. Salvador, BA, Brasil / Universidade Federal da Bahia. Instituto de Ciências da Saúde. Salvador, BA, BrasilUniversidade Federal da Bahia. Complexo Hospital Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil / National Institute of Science and Technology–Tropical Disease. Salvador, BA, Brasil / Universidade Federal da Bahia. Instituto de Ciências da Saúde. Salvador, BA, BrasilUniversidade Federal da Bahia. Complexo Hospital Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, BrasilPentoxifylline is a tumor necrosis factor-α (TNF-α) inhibitor that also attenuates the immune response and decreases tissue inflammation. The association of pentoxifylline with antimony improves the cure rate of mucosal and cutaneous leishmaniasis. In this randomized and double blind pilot trial, cure rate was higher, although not significant, in patients who received antimony plus pentoxifylline than in those patients receiving antimony plus placebo. A significant decrease in TNF-α and interferon-γ (IFN-γ) levels during therapy was more pronounced in the antimony plus pentoxifylline group, whereas CCL-3 (Chemokine [C-C motif] ligand 3) decreased similarly in both groups. The increased levels of CXCL-9 (Chemokine [C-X-C motif] ligand 9) during therapy were lower in the antimony plus pentoxifylline group. Therapy with pentoxifylline modifies cytokines and chemokines production, which may be associated with therapeutic outcome.engAmerican Society of Tropical Medicine and HygieneLeishmaniose CutâneaPentoxifilinaFator de necrose tumoral alfaMétodo duplo-cegoAdultoHumanosLeishmaniasis, CutaneousPentoxifyllineTumor Necrosis Factor-alphaDouble-Blind MethodAdultHumansClinical and immunological outcome in cutaneous leishmaniasis patients treated with pentoxifyllineinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/24887/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINALBrito G Clinical and Immunological Outcome....pdfBrito G Clinical and Immunological Outcome....pdfapplication/pdf720311https://www.arca.fiocruz.br/bitstream/icict/24887/2/Brito%20G%20Clinical%20and%20Immunological%20Outcome....pdfc5e6a8f9478077250632603fa6ddd142MD52TEXTBrito G Clinical and Immunological Outcome....pdf.txtBrito G Clinical and Immunological Outcome....pdf.txtExtracted texttext/plain19615https://www.arca.fiocruz.br/bitstream/icict/24887/3/Brito%20G%20Clinical%20and%20Immunological%20Outcome....pdf.txt9473f0a975019bb16419452288fa872fMD53icict/248872023-03-15 14:33:09.588oai:www.arca.fiocruz.br:icict/24887Q0VTU8ODTyBOw4NPIEVYQ0xVU0lWQSBERSBESVJFSVRPUyBBVVRPUkFJUwoKQW8gYWNlaXRhciBvcyBURVJNT1MgZSBDT05EScOHw5VFUyBkZXN0YSBDRVNTw4NPLCBvIEFVVE9SIGUvb3UgVElUVUxBUiBkZSBkaXJlaXRvcwphdXRvcmFpcyBzb2JyZSBhIE9CUkEgZGUgcXVlIHRyYXRhIGVzdGUgZG9jdW1lbnRvOgoKKDEpIENFREUgZSBUUkFOU0ZFUkUsIHRvdGFsIGUgZ3JhdHVpdGFtZW50ZSwgw6AgRklPQ1JVWiAtIEZVTkRBw4fDg08gT1NXQUxETyBDUlVaLCBlbQpjYXLDoXRlciBwZXJtYW5lbnRlLCBpcnJldm9nw6F2ZWwgZSBOw4NPIEVYQ0xVU0lWTywgdG9kb3Mgb3MgZGlyZWl0b3MgcGF0cmltb25pYWlzIE7Dg08KQ09NRVJDSUFJUyBkZSB1dGlsaXphw6fDo28gZGEgT0JSQSBhcnTDrXN0aWNhIGUvb3UgY2llbnTDrWZpY2EgaW5kaWNhZGEgYWNpbWEsIGluY2x1c2l2ZSBvcyBkaXJlaXRvcwpkZSB2b3ogZSBpbWFnZW0gdmluY3VsYWRvcyDDoCBPQlJBLCBkdXJhbnRlIHRvZG8gbyBwcmF6byBkZSBkdXJhw6fDo28gZG9zIGRpcmVpdG9zIGF1dG9yYWlzLCBlbQpxdWFscXVlciBpZGlvbWEgZSBlbSB0b2RvcyBvcyBwYcOtc2VzOwoKKDIpIEFDRUlUQSBxdWUgYSBjZXNzw6NvIHRvdGFsIG7Do28gZXhjbHVzaXZhLCBwZXJtYW5lbnRlIGUgaXJyZXZvZ8OhdmVsIGRvcyBkaXJlaXRvcyBhdXRvcmFpcwpwYXRyaW1vbmlhaXMgbsOjbyBjb21lcmNpYWlzIGRlIHV0aWxpemHDp8OjbyBkZSBxdWUgdHJhdGEgZXN0ZSBkb2N1bWVudG8gaW5jbHVpLCBleGVtcGxpZmljYXRpdmFtZW50ZSwKb3MgZGlyZWl0b3MgZGUgZGlzcG9uaWJpbGl6YcOnw6NvIGUgY29tdW5pY2HDp8OjbyBww7pibGljYSBkYSBPQlJBLCBlbSBxdWFscXVlciBtZWlvIG91IHZlw61jdWxvLAppbmNsdXNpdmUgZW0gUmVwb3NpdMOzcmlvcyBEaWdpdGFpcywgYmVtIGNvbW8gb3MgZGlyZWl0b3MgZGUgcmVwcm9kdcOnw6NvLCBleGliacOnw6NvLCBleGVjdcOnw6NvLApkZWNsYW1hw6fDo28sIHJlY2l0YcOnw6NvLCBleHBvc2nDp8OjbywgYXJxdWl2YW1lbnRvLCBpbmNsdXPDo28gZW0gYmFuY28gZGUgZGFkb3MsIHByZXNlcnZhw6fDo28sIGRpZnVzw6NvLApkaXN0cmlidWnDp8OjbywgZGl2dWxnYcOnw6NvLCBlbXByw6lzdGltbywgdHJhZHXDp8OjbywgZHVibGFnZW0sIGxlZ2VuZGFnZW0sIGluY2x1c8OjbyBlbSBub3ZhcyBvYnJhcyBvdQpjb2xldMOibmVhcywgcmV1dGlsaXphw6fDo28sIGVkacOnw6NvLCBwcm9kdcOnw6NvIGRlIG1hdGVyaWFsIGRpZMOhdGljbyBlIGN1cnNvcyBvdSBxdWFscXVlciBmb3JtYSBkZQp1dGlsaXphw6fDo28gbsOjbyBjb21lcmNpYWw7CgooMykgUkVDT05IRUNFIHF1ZSBhIGNlc3PDo28gYXF1aSBlc3BlY2lmaWNhZGEgY29uY2VkZSDDoCBGSU9DUlVaIC0gRlVOREHDh8ODTyBPU1dBTERPCkNSVVogbyBkaXJlaXRvIGRlIGF1dG9yaXphciBxdWFscXVlciBwZXNzb2Eg4oCTIGbDrXNpY2Egb3UganVyw61kaWNhLCBww7pibGljYSBvdSBwcml2YWRhLCBuYWNpb25hbCBvdQplc3RyYW5nZWlyYSDigJMgYSBhY2Vzc2FyIGUgdXRpbGl6YXIgYW1wbGFtZW50ZSBhIE9CUkEsIHNlbSBleGNsdXNpdmlkYWRlLCBwYXJhIHF1YWlzcXVlcgpmaW5hbGlkYWRlcyBuw6NvIGNvbWVyY2lhaXM7CgooNCkgREVDTEFSQSBxdWUgYSBvYnJhIMOpIGNyaWHDp8OjbyBvcmlnaW5hbCBlIHF1ZSDDqSBvIHRpdHVsYXIgZG9zIGRpcmVpdG9zIGFxdWkgY2VkaWRvcyBlIGF1dG9yaXphZG9zLApyZXNwb25zYWJpbGl6YW5kby1zZSBpbnRlZ3JhbG1lbnRlIHBlbG8gY29udGXDumRvIGUgb3V0cm9zIGVsZW1lbnRvcyBxdWUgZmF6ZW0gcGFydGUgZGEgT0JSQSwKaW5jbHVzaXZlIG9zIGRpcmVpdG9zIGRlIHZveiBlIGltYWdlbSB2aW5jdWxhZG9zIMOgIE9CUkEsIG9icmlnYW5kby1zZSBhIGluZGVuaXphciB0ZXJjZWlyb3MgcG9yCmRhbm9zLCBiZW0gY29tbyBpbmRlbml6YXIgZSByZXNzYXJjaXIgYSBGSU9DUlVaIC0gRlVOREHDh8ODTyBPU1dBTERPIENSVVogZGUKZXZlbnR1YWlzIGRlc3Blc2FzIHF1ZSB2aWVyZW0gYSBzdXBvcnRhciwgZW0gcmF6w6NvIGRlIHF1YWxxdWVyIG9mZW5zYSBhIGRpcmVpdG9zIGF1dG9yYWlzIG91CmRpcmVpdG9zIGRlIHZveiBvdSBpbWFnZW0sIHByaW5jaXBhbG1lbnRlIG5vIHF1ZSBkaXogcmVzcGVpdG8gYSBwbMOhZ2lvIGUgdmlvbGHDp8O1ZXMgZGUgZGlyZWl0b3M7CgooNSkgQUZJUk1BIHF1ZSBjb25oZWNlIGEgUG9sw610aWNhIEluc3RpdHVjaW9uYWwgZGUgQWNlc3NvIEFiZXJ0byBkYSBGSU9DUlVaIC0gRlVOREHDh8ODTwpPU1dBTERPIENSVVogZSBhcyBkaXJldHJpemVzIHBhcmEgbyBmdW5jaW9uYW1lbnRvIGRvIHJlcG9zaXTDs3JpbyBpbnN0aXR1Y2lvbmFsIEFSQ0EuCgpBIFBvbMOtdGljYSBJbnN0aXR1Y2lvbmFsIGRlIEFjZXNzbyBBYmVydG8gZGEgRklPQ1JVWiAtIEZVTkRBw4fDg08gT1NXQUxETyBDUlVaIHJlc2VydmEKZXhjbHVzaXZhbWVudGUgYW8gQVVUT1Igb3MgZGlyZWl0b3MgbW9yYWlzIGUgb3MgdXNvcyBjb21lcmNpYWlzIHNvYnJlIGFzIG9icmFzIGRlIHN1YSBhdXRvcmlhCmUvb3UgdGl0dWxhcmlkYWRlLCBzZW5kbyBvcyB0ZXJjZWlyb3MgdXN1w6FyaW9zIHJlc3BvbnPDoXZlaXMgcGVsYSBhdHJpYnVpw6fDo28gZGUgYXV0b3JpYSBlIG1hbnV0ZW7Dp8OjbwpkYSBpbnRlZ3JpZGFkZSBkYSBPQlJBIGVtIHF1YWxxdWVyIHV0aWxpemHDp8Ojby4KCkEgUG9sw610aWNhIEluc3RpdHVjaW9uYWwgZGUgQWNlc3NvIEFiZXJ0byBkYSBGSU9DUlVaIC0gRlVOREHDh8ODTyBPU1dBTERPIENSVVoKcmVzcGVpdGEgb3MgY29udHJhdG9zIGUgYWNvcmRvcyBwcmVleGlzdGVudGVzIGRvcyBBdXRvcmVzIGNvbSB0ZXJjZWlyb3MsIGNhYmVuZG8gYW9zIEF1dG9yZXMKaW5mb3JtYXIgw6AgSW5zdGl0dWnDp8OjbyBhcyBjb25kacOnw7VlcyBlIG91dHJhcyByZXN0cmnDp8O1ZXMgaW1wb3N0YXMgcG9yIGVzdGVzIGluc3RydW1lbnRvcy4KRepositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-03-15T17:33:09Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
| dc.title.pt_BR.fl_str_mv |
Clinical and immunological outcome in cutaneous leishmaniasis patients treated with pentoxifylline |
| title |
Clinical and immunological outcome in cutaneous leishmaniasis patients treated with pentoxifylline |
| spellingShingle |
Clinical and immunological outcome in cutaneous leishmaniasis patients treated with pentoxifylline Brito, Maria das Graças de Oliveira Leishmaniose Cutânea Pentoxifilina Fator de necrose tumoral alfa Método duplo-cego Adulto Humanos Leishmaniasis, Cutaneous Pentoxifylline Tumor Necrosis Factor-alpha Double-Blind Method Adult Humans |
| title_short |
Clinical and immunological outcome in cutaneous leishmaniasis patients treated with pentoxifylline |
| title_full |
Clinical and immunological outcome in cutaneous leishmaniasis patients treated with pentoxifylline |
| title_fullStr |
Clinical and immunological outcome in cutaneous leishmaniasis patients treated with pentoxifylline |
| title_full_unstemmed |
Clinical and immunological outcome in cutaneous leishmaniasis patients treated with pentoxifylline |
| title_sort |
Clinical and immunological outcome in cutaneous leishmaniasis patients treated with pentoxifylline |
| author |
Brito, Maria das Graças de Oliveira |
| author_facet |
Brito, Maria das Graças de Oliveira Dourado, Mayra Elizabeth Ferreira Polari, Ludmila Celestino, Daniela Carvalho, Lucas Pedreira de Queiroz, Adriano Carvalho Filho, Edgar Marcelino Machado, Paulo Roberto Lima Passos, Sara Timoteo |
| author_role |
author |
| author2 |
Dourado, Mayra Elizabeth Ferreira Polari, Ludmila Celestino, Daniela Carvalho, Lucas Pedreira de Queiroz, Adriano Carvalho Filho, Edgar Marcelino Machado, Paulo Roberto Lima Passos, Sara Timoteo |
| author2_role |
author author author author author author author author |
| dc.contributor.author.fl_str_mv |
Brito, Maria das Graças de Oliveira Dourado, Mayra Elizabeth Ferreira Polari, Ludmila Celestino, Daniela Carvalho, Lucas Pedreira de Queiroz, Adriano Carvalho Filho, Edgar Marcelino Machado, Paulo Roberto Lima Passos, Sara Timoteo |
| dc.subject.other.pt_BR.fl_str_mv |
Leishmaniose Cutânea Pentoxifilina Fator de necrose tumoral alfa Método duplo-cego Adulto Humanos |
| topic |
Leishmaniose Cutânea Pentoxifilina Fator de necrose tumoral alfa Método duplo-cego Adulto Humanos Leishmaniasis, Cutaneous Pentoxifylline Tumor Necrosis Factor-alpha Double-Blind Method Adult Humans |
| dc.subject.en.pt_BR.fl_str_mv |
Leishmaniasis, Cutaneous Pentoxifylline Tumor Necrosis Factor-alpha Double-Blind Method Adult Humans |
| description |
CARVALHO FILHO, Edgar Marcelino de. “Documento produzido em parceria ou por autor vinculado à Fiocruz, mas não consta à informação no documento”. |
| publishDate |
2014 |
| dc.date.issued.fl_str_mv |
2014 |
| dc.date.accessioned.fl_str_mv |
2018-02-20T15:58:56Z |
| dc.date.available.fl_str_mv |
2018-02-20T15:58:56Z |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.citation.fl_str_mv |
BRITO, M. G. O. et al. Clinical and immunological outcome in cutaneous leishmaniasis patients treated with pentoxifylline. American Journal of Tropical Medicine and Hygiene, v. 90, n. 4, p. 617–620, 2014. |
| dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/24887 |
| dc.identifier.issn.pt_BR.fl_str_mv |
0002-9637 |
| dc.identifier.doi.none.fl_str_mv |
10.4269/ajtmh.12-0729 |
| identifier_str_mv |
BRITO, M. G. O. et al. Clinical and immunological outcome in cutaneous leishmaniasis patients treated with pentoxifylline. American Journal of Tropical Medicine and Hygiene, v. 90, n. 4, p. 617–620, 2014. 0002-9637 10.4269/ajtmh.12-0729 |
| url |
https://www.arca.fiocruz.br/handle/icict/24887 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
American Society of Tropical Medicine and Hygiene |
| publisher.none.fl_str_mv |
American Society of Tropical Medicine and Hygiene |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
| instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
| instacron_str |
FIOCRUZ |
| institution |
FIOCRUZ |
| reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| collection |
Repositório Institucional da FIOCRUZ (ARCA) |
| bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/24887/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/24887/2/Brito%20G%20Clinical%20and%20Immunological%20Outcome....pdf https://www.arca.fiocruz.br/bitstream/icict/24887/3/Brito%20G%20Clinical%20and%20Immunological%20Outcome....pdf.txt |
| bitstream.checksum.fl_str_mv |
5a560609d32a3863062d77ff32785d58 c5e6a8f9478077250632603fa6ddd142 9473f0a975019bb16419452288fa872f |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
| repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
| _version_ |
1798324777572630528 |